Histone deacetylases (HDACs) play a key role in homeostasis of protein acetylation in histones and other proteins and in regulating fundamental cellular activities such as transcription. A wide range of brain disorders are associated with imbalances in protein acetylation levels and transcriptional dysfunctions. Treatment with various HDAC inhibitors can correct these deficiencies and has emerged as a promising new strategy for therapeutic intervention in neurodegenerative disease. Here, we review and discuss intriguing recent developments in the use of HDAC inhibitors to combat neurodegenerative conditions in cellular and disease models. HDAC inhibitors have neuroprotective, neurotrophic and antiinflammatory properties; improvements in neurological performance, learning/memory and other disease phenotypes are frequently seen in these models. We discuss the targets and mechanisms underlying these effects of HDAC inhibition and comment on the potential for some HDAC inhibitors to prove clinically effective in the treatment of neurodegenerative disorders.
Introduction
Acetylation and deacetylation of histone proteins associated with chromatin plays a pivotal role in the epigenetic regulation of transcription and other functions in cells, including neurons [1] [2] [3] [4] . Histone acetyltransferases (HATs) and histone deacetylases (HDACs) catalyze the acetylation and deacetylation, respectively, of histone proteins at Lys (K) residues. The interplay between HATs and HDACs alters the net balance of histone acetylation levels, thereby remodeling chromatin structure (Figure 1) . In general, an increase in protein acetylation at histonetails results in a more open and relaxed chromatin conformation, thus facilitating transcription factor interaction with specific gene promoters and activating gene expression. HDACs often function as a component of the transcriptional repressor complex to silence gene expression and induce chromatin compaction through histone protein deacetylation. Accordingly, HDAC inhibition shifts the balance towards enhanced histone acetylation, chromatin relaxation and gene expression.
Imbalance between the activities of HATs and HDACs could lead to disease states. For example, mutation and loss of activity of the HAT, cyclic AMP response element binding protein (CREB)-binding protein (CBP), is causative for Rubinstein-Taybi syndrome, a developmental disorder characterized by mental retardation [5] . In addition to histones, HATs and HDACs also use a number of non-histone proteins as their substrates, notably tubulin and transcription factors such as the tumor suppressor p53, Sp1, Smad7, CREB, the pleiotropic transcription factor NF-kB, and signal transducers and activators of transcription-1 (STAT-1) (reviewed in Refs. [4, 6] ). In this article we first briefly describe the classification and isoforms of HDACs and the properties of a number of isoformnonselective and more selective HDAC inhibitors. We then review the current research using various HDAC inhibitors in cellular and animal models of neurodegenerative diseases. The beneficial effects and potential caveats of these studies are discussed. Finally, proposed future directions are addressed.
HDACs and HDAC inhibitors HDAC enzymes are evolutionarily conserved among many species. In humans, HDAC enzymes can be divided into four major classes based on their homology to yeast HDACs (reviewed in Refs. [7, 8] ). Class I HDACs include HDAC1, 2, 3 and 8; these are related to the yeast enzyme Rpd3. Class II HDACs include HDAC4, 5, 6, 7, 9 and 10, and are related to the yeast protein HDA1; class II HDACs are further divided into two subclasses -IIa (HDAC4, 5, 7 and 9) and IIb (HDAC6 and 10) -according to their structural similarities. Class I and II HDACs have been most extensively investigated for their roles in the central nervous system (CNS). Class III HDACs show dependence of nicotinamide adenine dinucleotide (NAD + ) and are referred to as sirtuins owing to their homology to the yeast HDAC Sir2. This class includes SIRT1-SIRT7 [9] . HDAC11, the most recently identified isoform, is a class IV HDAC due to its distinct structure [10] . Class I, II, and IV are zinc-dependent enzymes.
A variety of isoform-nonselective and selective HDAC inhibitors have been developed, both synthetically derived and from natural sources (reviewed in Ref. [6] ). Among the relatively nonselective HDAC inhibitors, trichostatin A (TSA) and suberoylanilide hydroxamic acid (vorinostat, also known as SAHA) inhibit most zinc-dependent HDACs including HDAC6, and are permeable to the blood-brain barrier (BBB). The hydroxamate moiety of these compounds appears to bind the zinc ion at the HDAC active site to inactivate the enzyme. Sodium butyrate and 4-phenylbutyrate are fatty acid derivatives that inhibit most class I and II HDACs. However, butyrate does not appear to inhibit HDAC6 because the acetylation levels of 
